Novartis

EPIK-B2 | CYBL719G12301

NCT04208178

JCP075

Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

Status:

Opening Soon

26459-200.png

III

Phase

Line of Therapy.png

2nd+

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

PIK3CA

Investigational

Product

Alpelisib (BYL719)

Treatment Arms

o Experimental: Part 1: Alpelisib + Trastuzumab + Pertuzumab

o Experimental: Part 2: Alpelisib + Trastuzumab + Pertuzumab

o Placebo Comparator: Part 2: Alpelisib matching Placebo + Trastuzumab + Pertuzumab